Celsion, Corp. (NASDAQ:CLSN) Tries to Regain Levels before Crash
Celsion, Corp. (NASDAQ:CLSN) is yet another ambitions biotechnological company cut short by a sudden reversal of fortune. Just on the verge of a stage III trial with expected positive outcomes, CLSN crashed from $4.30 to below a dollar in a day as the results were less than pleasing. Since then, CLSN has been trying to make a recovery and regain trust. The last few days saw CLSN rocket from a dollar to $1.87 on days marking 40 or even 50 million shares bought. 
Recently, the drug trial went through evaluation and showed the data were more hopeful than initially thought. The drug is still far away from market, but for CLSN this means a fast recovery of previous levels, especially if enough investors show interest. 
Adding to the bullish attitude are the financial records of the company, which are solid enough for its reputation and drive to achieve:
- $20.3 million cash
- $46.4 million current assets
- $7.6 million current liabilities
- $650,964 net loss
So far, CLSN is on top of its game with working capital and gaining enough from older licenses, but in the biopharmaceutical sector a ticker is as good as its latest promises. The marketing success is not even as important as the potential for larger and more lucrative deals with a unique patented treatment, the cash cow for any drug developer.
Such crashes are wiping out a lot of value, but they also posit a unique opportunity, and they are not entirely unpredictable. The story of CLSN resembles that of Titan Pharmaceutlcals, Inc. (OTCBB:TTNP), which shed 75% of its value on unfavorable commentaries from the FDA. Later, the recovery was not complete as the approval for its anti-opioid treatment technology still received more negative than positive feedback.
Currently, CLSN has a promising pipeline of drugs- the current Phase III trial awaiting further development, three stage 1-2 trials, and two more projects at the pre-clinical stage. All focus on cancer treatments, and use the patent-protected ThermoDox delivery systems, relying on thermally activated particles for targeted drug delivery. All the drug trials and successes are also being promoted among the mainstream medical community, suggesting a possibility for successful adoption in active treatment.
In 2012, CLSN showed enormous potential to climb, moving from $2 to about $9 on all the bullish expectations. Still, it is best to recall that the ticker is still moving primarily on news, and as other drug companies will tend to react very badly to any negative news. So stay away unless you can afford to absorb the bad news.
